The pharmaceutical industry as a medicines provider

David Henry, Joel Lexchin

Research output: Contribution to journalArticleResearchpeer-review

105 Citations (Scopus)

Abstract

Rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, millions of individuals do not have access to essential drugs. Drug development is failing to address the major health needs of these countries. The prices of patented medicines usually far exceed the marginal costs of their production; the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products. There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and to advocate differential pricing of essential drugs. How these actions will help countries that lack domestic production capacity is unclear. Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries.

Original languageEnglish
Pages (from-to)1590-1595
Number of pages6
JournalLancet
Volume360
Issue number9345
DOIs
Publication statusPublished - 16 Nov 2002
Externally publishedYes

Fingerprint

Essential Drugs
Drug Industry
Developing Countries
Costs and Cost Analysis
Intellectual Property
Ownership
Licensure
Pharmaceutical Preparations
Industry
Organizations
Health

Cite this

Henry, David ; Lexchin, Joel. / The pharmaceutical industry as a medicines provider. In: Lancet. 2002 ; Vol. 360, No. 9345. pp. 1590-1595.
@article{d6c0976f15e842f1a008f45b2e659de3,
title = "The pharmaceutical industry as a medicines provider",
abstract = "Rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, millions of individuals do not have access to essential drugs. Drug development is failing to address the major health needs of these countries. The prices of patented medicines usually far exceed the marginal costs of their production; the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products. There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and to advocate differential pricing of essential drugs. How these actions will help countries that lack domestic production capacity is unclear. Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries.",
author = "David Henry and Joel Lexchin",
year = "2002",
month = "11",
day = "16",
doi = "10.1016/S0140-6736(02)11527-3",
language = "English",
volume = "360",
pages = "1590--1595",
journal = "Lancet",
issn = "0140-6736",
publisher = "Elsevier",
number = "9345",

}

The pharmaceutical industry as a medicines provider. / Henry, David; Lexchin, Joel.

In: Lancet, Vol. 360, No. 9345, 16.11.2002, p. 1590-1595.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The pharmaceutical industry as a medicines provider

AU - Henry, David

AU - Lexchin, Joel

PY - 2002/11/16

Y1 - 2002/11/16

N2 - Rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, millions of individuals do not have access to essential drugs. Drug development is failing to address the major health needs of these countries. The prices of patented medicines usually far exceed the marginal costs of their production; the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products. There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and to advocate differential pricing of essential drugs. How these actions will help countries that lack domestic production capacity is unclear. Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries.

AB - Rising prices of medicines are putting them beyond the reach of many people, even in rich countries. In less-developed countries, millions of individuals do not have access to essential drugs. Drug development is failing to address the major health needs of these countries. The prices of patented medicines usually far exceed the marginal costs of their production; the industry maintains that high prices and patent protection are necessary to compensate for high development costs of innovative products. There is controversy over these claims. Concerns about the harmful effects of the international system of intellectual property rights have led the World Trade Organization to relax the demands placed on least developed countries, and to advocate differential pricing of essential drugs. How these actions will help countries that lack domestic production capacity is unclear. Better access to essential drugs may be achieved through voluntary licensing arrangements between international pharmaceutical companies and manufacturers in developing countries.

UR - http://www.scopus.com/inward/record.url?scp=0037121236&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(02)11527-3

DO - 10.1016/S0140-6736(02)11527-3

M3 - Article

VL - 360

SP - 1590

EP - 1595

JO - Lancet

JF - Lancet

SN - 0140-6736

IS - 9345

ER -